PRESS
03/24/08
SAN DIEGO, CA (March 24, 2008) – Sangart, Inc. today announced that it has completed enrollment in a Phase III trial of its lead product Hemospan®.
03/11/08
SAN DIEGO, CA (March 11, 2008) – Sangart, Inc., a privately held biopharmaceutical company focused on the research, development and commercialization of oxygen transport agents, today announced that an independent data safety monitoring board (DSMB) has recommended the continuation of both Phase III clinical trials of Sangart’s lead blood substitute product, Hemospan®, under current protocols.
01/07/08
SAN DIEGO, CA (January 7, 2008) – Sangart, Inc. announced today that it has started testing its lead product, Hemospan®, in a Phase II clinical study involving chronic critical limb ischemia (CCLI) patients.
12/12/07
SAN DIEGO, CA (December 12 , 2007) – Sangart, Inc. today announced that an independent data safety monitoring board (DSMB) has recommended the continuation of both Phase III clinical trials of Sangart’s lead blood substitute product, Hemospan®, under current protocols.
04/04/07
Sangart, Inc. announced today that it received $50 million in new equity funding from existing investors, led by Leucadia National Corporation. The Series F round brings the total amount raised by the company since its inception in 1998 to more than $120 million. This financing round also included warrants which, if exercised, could provide an additional $50 million in future funding.
02/13/07
Sangart, Inc. announced that it has begun enrolling patients in two parallel European Phase III trials on Hemospan®, its lead drug candidate. Hemospan is the first oxygen therapeutic specifically engineered to target oxygen delivery to tissues.
12/20/06
Sangart, Inc. today announced the publication of results from its Phase II clinical trial of Hemospan® in patients undergoing major orthopedic surgery.
12/15/05
Sangart, Inc. today announced that the U.S. Patent and Trademark Office has granted to Sangart a new patent entitled “Methods and Compositions For Oxygen Transport Comprising A High Oxygen Affinity Modified Hemoglobin.”
11/01/05
Sangart, Inc. today announced positive results from a Phase II clinical trial involving Hemospan® (MP4) in hip surgery patients.
07/25/05
Sangart, Inc. today announced that it has leased a new facility to which it plans to relocate by year end.
07/19/05
Sangart, Inc. announced today the initiation of a U.S. Phase II clinical trial involving Hemospan® (MP4).
02/24/05
Sangart, Inc. announced today the completion of patient enrollment in its Phase II clinical trial involving Hemospan® (MP4), a hemoglobin-based oxygen carrier designed to serve as an alternative for blood transfusions.
09/08/04
Sangart, Inc. announced today the initiation of a Phase II clinical trial involving Hemospan™ (MP4), a hemoglobin-based oxygen carrier designed to serve as an alternative for blood transfusions. Sangart also announced its receipt of a joint grant from the National Heart Lung and Blood Institute of the National Institutes of Health and the United States Army Medical Research and Material Command.
04/12/04
Sangart, Inc. announced today that it has received approval from the Swedish Medical Products Agency (MPA) to conduct a Phase II clinical trial for Hemospan?.
03/11/04
Sangart announced today positive results from its Phase Ib/II clinical trial involving Hemospan™ (MP4), a hemoglobin-based oxygen carrier designed to serve as an alternative for blood transfusions.
09/05/03
Sangart announced today the closing of a Preferred Stock private placement financing of $12 million.
07/23/03
Sangart announced today the results of its study showing that polyethylene glycol-modified human hemoglobin (MalPEG-Hb) improves blood flow and tissue oxygenation after hemorrhagic shock.
05/08/03
Sangart announced today the initiation of its Phase Ib/II clinical trial for Hemospan (MP4) in Stockholm, Sweden.
12/13/02
Sangart, a biopharmaceutical company developing oxygen transport agents, announced today that it has received approval from the Swedish Medical Product Agency (MPA) to conduct a Phase Ib/II clinical trial for Hemospan(TM).
12/03/02
Sangart announced today that its Chairman and CEO, Robert M. Winslow, M.D., will make a presentation titled: Autoregulation and Vasoconstriction: Foundation for a New Generation of Blood Substitutes, at the ASH 44th Annual Meeting on December 9, 2002.
10/21/02
Sangart announced today that its Chairman and CEO, Robert M. Winslow, M.D., will present "The New Physiology of Oxygen Transfer in the Microcirculation and Implications for the Design of Next-generation Oxygen Therapeutics" at the AABB in Orlando, FL October 26th.
08/27/02
Sangart today announced that it received a Notice of Allowance from the United States Patent and Trademark Office for a new patent application.
08/22/02
Sangart, Inc. announced today that it is scheduled to present its Phase I data for the Company's lead product, Hemospan, a product designed to serve as an alternative for red blood cell transfusions.
08/07/02
Gambro subsidiary Gambro BCT has together with its strategic partner Sangart demonstrated the pathogen reduction efficacy of Gambro`s Pathogen Reduction Technology in the preparation of Sangart`s oxygen transport agent Hemospan.
08/02/02
Sangart today announced successful Phase I clinical trial results for Hemospan (TM) product designed to serve as an alternative for red blood cell transfusions.
02/01/02
Sangart announced today the election of Dr. Curtis Scribner, formerly Chief of the Blood Division at the FDA, to their Board of Directors.
07/27/01
Gambro's Pathogen Eradication Technology, PET, will be used in the production of Sangart's blood substitute product.